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Diarrhea caused by Campylobacterjejuni/coli is one of the 
most common bacterial intestinal infections in our 
region (province of Styria, 1.2 million inhabitants). 
Most of the cases appear to be mild and self-limiting, 
making antibiotic treatment necessary only under 
special conditions. Macrolides would be the reconi- 
mended antibiotics for CavnZlylobacter-related illness. 
Usually, however, ciprofloxacin is prescribed empirically 
in our region [I ,2]. 
At the Institute of Hygiene, University of Graz, 
Carnpylobacter spp. have been tested for resistance to 
nalidixic acid to detect the so-called NARTC (nalidixic 
acid-resistant thermophilic campylobacter) since 1988. 
Nalidixic acid-resistant strains were rare in 1988-90, 
but in the summer of 1991 we found a notable increase 
of resistant isolates, so we started to test ciprofloxacin 
and erythromycin routinely in 1992. Even during the 
first year we found a remarkable increase in cipro- 
floxacin resistance [3] and this has continued until now 
(Figure 1). 
To determine resistance patterns throughout the 
province of Styria, the three main Styrian laboratories 
have collected and evaluated data from the last 2 years 
(1996 and 1997). In total, 58 505 specimens of feces 
were examined and 1315 isolates of Campylobacter spp. 
were obtained from 1158 patients (specimen positivity 
2.25%). Species differentiation of 935 first isolates from 
individual patients revealed 94.1% C. jejuni and 5.9% 
C. coli. Nearly 30% of the isolates were from patients 
whose diarrheal illness had necessitated hospital treat- 
ment. The age distribution showed an excess of cases 
among children from 0 to 10 years (30%) and a second 
peak among the 20-30-year-olds. Most of these in- 
fections were acquired in our region; the number of 
infections acquired abroad was less than 5%. 
In all three laboratories, patterns of resistance of 
Campylobacter spp. to erythromycin (1 5 pg), nalidixic 
acid (30 pg) and ciprofloxacin (5 pg) were tested by 
disk diffusion performed on Mueller-Hinton agar 
(Oxoid, Basingstoke, UK) supplemented with 5% blood. 
All strains were incubated in a micro-aerophilic atmo- 
sphere at  42°C and read after 24-48 h. The following 
zone diameters (in mm) were used: erythromycin, 
>=23  susceptible, <=13 resistant; nalidixic acid, >=19 
susceptible, <=13 resistant; ciprofloxacin, >=21 
susceptible, < =15 resistant. In doubtful cases (nalidixic 
acid resistant and ciprofloxacin susceptible or 
intermediate), an additional Etest was performed 
according to the recommen-dations of Baker [4] for 
further confirmation and detection of type 2 mutants 
[5]. The following break-points of ciprofloxacin were 
used: MIC > = 4  mg/L, resistant; MIC < = 1  mg/L, 
susceptible. The results of these tests (only first isolates 
were used) are shown in Table 1. No connection was 
apparent between cipro-floxacin resistance and age or 
geographic distribution. A difference, however, occurred 
between C. jejuni and C. coli. Of  935 species-differen- 
tiated isolates, 880 were C. jejuni with a ciprofloxacin 
resistance of 27.4% and erythromycin resistance of 
0.7%, while the cipro-floxacin and erythromycin 
resistance of 55 strains of C. coli reached 47.3% and 
5.5%, respectively. 
The reason for this development may have been a 
regulation of the Austrian government (‘Geflugel- 
hygieneverordnung’), which was passed in the summer 
of 1991 and came into force on 1 January, 1992 with 
the aim of reducing the incidence of salmonellosis 
in Austria. This regulation laid down a number of 
measures, e.g. the testing of all poultry flocks for 
Salmonella spp. prior to slaughtering, with only 
Salmonella-free flocks being released for slaughter. This 
measure increasingly induced veterinarians to use anti- 
biotics in the poultry industry, especially enrofloxacin 
(Baytril), a quinolone closely related to ciprofloxacin. 
This development of resistance after the introduction of 
enrofloxacin in veterinary medicine was first described 
by Endtz et a1 in The Netherlands [6,7]; since that time, 
further publications reporting similar findings have 
become available [8-111. In Austria, enrofloxacin was 
introduced in the summer of 1989, but a large degree 
of overuse was initiated by the government regulation 
Table 1 Susceptibility of 1149 Campylobacter spp. (first 
isolates from individual patients) to erythromycin, nalidixic 
acid and ciprofloxacin 
Resistant to Resistant to Resistant to 
Number of erythromycm nalidixic acid ciprofloxacin 
isolates (“w (”/.I (“A) 
1996 568 1.4 25.9 25.2 
1997 581 0.3 34.9 34.1 
Total 1149 0.9 30.4 29.7 
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Figure 1 Development of quinolone resistance in Carnpylobacter jejtmi/coli at the Institute of Hygiene in Graz. 
mentioned above. Hirschl et al. had found no resistant 
C. jejcrni/coli in Austria before 1988 [12]. Taking into 
consideration the results we obtained at the Institute 
of Hygiene when testing resistance to the quinolone 
nalidixic acid from 1988 to 1991, a conclusion can be 
drawn that there was a low ciprofloxacin resistance rate 
before this regulation was introduced. 
In conclusion, the resistance patterns in our region 
do not justify empirical treatment of diarrhea with 
ciprofloxacin. In severe cases of diarrhea, specimens 
should be tested for causative pathogens and their anti- 
microbial susceptibility. In the few cases of Campylo- 
bacter-related diarrhea requiring antibiotic treatment, 
macrolides should be used. Quinolones in veterinary 
medicine should be reconsidered and should not be the 
antibiotics of first choice. Legal hygiene measures in 
Austria ('Geflugel-hygieneverordnung') may require 
alteration in view of recent developments. 
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